CytoReason raised $80 million from Nvidia, Pfizer, Thermo Fisher, and OurCrowd to expand its AI models and open a Cambridge office. Their Pfizer partnership includes a $20 million investment. Mikael Dolsten praised AI's healthcare potential. Six top pharma companies use CytoReason's platform for data-driven decisions and drug development pathways. Read The Rest at :
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.
